Sector News

Amgen is eyeing heftier deals, but so are its biggest rivals

March 8, 2016
Life sciences

It’s no secret that Amgen is scouting for deals. And now, its CFO says, it’s open to potentially larger deals than the ones it’s made in the past.

“We’re saying you shouldn’t be surprised if we do” a transaction on the heftier side, CFO David Meline told Bloomberg, noting that Amgen these days is “more energetic about being out there.”

But that doesn’t mean the California biotech is going to jump at any large target that crosses its path. On the contrary, it turned down some potential moves in the second half of 2015 that weren’t a perfect fit–and it plans to continue being selective.

“The hardest thing to do when you have money in the bank is to be disciplined,” Meline told the news service.

That’s amplified by the sound of investors pressuring the company to pull the trigger. Biopharma has been riding a red-hot deals streak over the past couple of years, and Amgen in particular could use a boost. Its blockbusters are high on the list for biosimilar copycats–Neupogen is already under attack in the U.S. from Novartis trailblazer Zarxio–and in 2014, it fueled a restructuring with a 1,100 job-chop that brought its layoff tally to 4,000. Some analysts have even lobbied for a breakup, a la Amgen’s Big Pharma peers.

CEO Robert Bradway, though, hasn’t been swayed into taking the plunge, with the company’s last major deal coming in 2013. That acquisition–a $10.4 billion Onyx Pharmaceuticals buyout–brought along Kyprolis, a cancer drug whose patient pool Amgen has been working to widen.

So who might Amgen be targeting? Its recent commitment to home in on 6 therapeutic categories provides some clues, Bloomberg notes. Cardiovascular and neuroscience are new focus areas for the company; in the former, Amgen has only new PCSK9 med Repatha and heart failure drug Corlanor, and in the latter, the Thousand Oaks-based drugmaker has no approved products.

But Amgen will have some competition at the dealmaking table. The industry has long had its eyes trained on Gilead Sciences, whose record-breaking hep C blockbusters have left it with a treasure trove of cash to work with. And analysts have suggested that Biogen–whose growth is slowing thanks to pressure in the MS space–may need to “eat or be eaten,” too.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”